Every 10-Q that ANI Pharmaceuticals, Inc. (ANIP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI Pharmaceuticals reported stronger results for the quarter and six months ended June 30, 2026. For the quarter, net revenues were $266,044 thousand, up from $211,371 thousand a year earlier, and net income was $24,711 thousand versus $8,549 thousand. Operating income rose to $40,460 thousand from $13,892 thousand.
For the first half of 2026, total net revenues reached $503,506 thousand compared with $408,493 thousand in 2025, and net income increased to $54,203 thousand from $24,230 thousand. Rare Disease and Brands contributed $293,630 thousand, including Cortrophin Gel at $192,245 thousand, ILUVIEN and YUTIQ at $37,973 thousand, and brand royalties and other revenues at $39,271 thousand; Generics and Other contributed $209,876 thousand.
Liquidity improved, with cash and cash equivalents of $360,212 thousand at June 30, 2026 versus $285,585 thousand at year-end 2025 and net cash provided by operating activities of $115,044 thousand in the first half. The company carries Term Loan A borrowings of $304,688 thousand and 2.25% Convertible Senior Notes of $309,009 thousand (both in thousands). Retained earnings shifted to a positive $31,104 thousand from an accumulated deficit of $23,099 thousand at December 31, 2025.
ANI Pharmaceuticals, Inc. reported strong results for the quarter ended March 31, 2026, with net revenues of $237.5 million, up from $197.1 million a year earlier. Net income rose to $29.5 million versus $15.7 million, driving diluted earnings per share to $1.28, compared with $0.69 in the prior-year period.
Growth was driven by Rare Disease and Brands, where net revenues increased to $128.2 million from $94.1 million, including $75.1 million from Cortrophin Gel and $19.3 million from ILUVIEN and YUTIQ. Generics and Other net revenues increased to $109.2 million from $103.0 million.
Operating income improved to $38.9 million from $26.2 million, helped by higher sales and a favorable contingent consideration fair value adjustment. Cash and cash equivalents grew to $311.2 million from $285.6 million at year-end, supported by $58.4 million of cash provided by operating activities, while total liabilities decreased modestly to $859.7 million from $899.7 million.
ANI Pharmaceuticals (ANIP) reported strong Q3 2025 results. Net revenues were $227.8 million, up from $148.3 million a year ago. Net income was $26.6 million versus a loss of $24.2 million, and diluted EPS was $1.13. Operating income reached $36.2 million, helped by higher sales in Rare Disease and Brands, especially Cortrophin Gel and the addition of ILUVIEN and YUTIQ.
Year-to-date, net revenues were $636.3 million versus $423.8 million. Operating cash flow was $154.9 million. Cash and cash equivalents were $262.6 million as of September 30, 2025. The company completed the Alimera acquisition in 2024 and in March 2025 expanded ILUVIEN’s U.S. label to include NIU-PS, shifting U.S. promotion from YUTIQ to ILUVIEN. As of October 31, 2025, there were 22,458,168 shares of common stock outstanding.
ANIP Q2-25 revenue jumped 53% YoY to $211.4 m, propelled by Cortrophin Gel (+66% to $81.6 m) and the first full quarter of ILUVIEN/YUTIQ sales ($22.3 m) acquired with Alimera. Generics grew 22% to $90.3 m.
Gross margin widened to 64.7% (58.2% LY) while SG&A climbed 55% on integration and commercial scale-up. Operating income rose to $13.9 m (6.6% margin) from $5.2 m; net income swung to $8.5 m, delivering diluted EPS of $0.36 versus a $0.14 loss. Six-month revenue is $408.5 m (+48%) with EPS of $1.05.
Cash reached $217.8 m as operating cash flow tripled to $110.8 m. Total debt remains high at $621.6 m (incl. $306.9 m converts), leaving net debt of ≈$404 m and leverage near 2.9× LTM sales. Intangible assets of $520 m and goodwill of $60.5 m reflect the Alimera deal; contingent consideration stands at $18.6 m.
Management stresses ongoing rare-disease momentum, manufacturing synergies and expanded market reach, but notes risks around debt covenants, rising rebate liabilities and Alimera integration.